RheumaView · Chapter 18 · Patient guide
Pregnancy, fertility and family planning in r-axSpA: what should be discussed before conception, during pregnancy and after delivery
Radiographic axial spondyloarthritis (r-axSpA) often begins during the years when people are thinking about:
In this chapter
- Start before pregnancy when possible
- Check your understanding 1
- Can women with r-axSpA become pregnant?
- When should difficulty conceiving be evaluated?
- NSAIDs can matter when trying to conceive
- Fertility and men with r-axSpA
- Do not stop a biologic automatically when pregnancy begins
- TNF inhibitors: the largest pregnancy experience
- Certolizumab is different in placental transfer
- Other TNF inhibitors cross the placenta more later in pregnancy
- Infant vaccination needs a medication-specific plan
- What about IL-17 inhibitors?
- What about JAK inhibitors?
- Check your understanding 2
- What about NSAIDs during pregnancy?
- “But NSAIDs are my main symptom treatment.”
- What about steroids?
- Pregnancy does not reliably switch axSpA “off”
- Check your understanding 3
- Pregnancy can change how symptoms feel
- What about MRI during pregnancy?
- Does r-axSpA make pregnancy high risk?
- Does r-axSpA mean I need a cesarean section?
- Hip disease can matter for delivery
- The spine matters for anesthesia planning
- When should anesthesiology be involved early?
- Check your understanding 4
- What happens after delivery?
- If a biologic was stopped during pregnancy, when can it be restarted?
- Breastfeeding and biologics
- JAK inhibitors are different during breastfeeding
- NSAIDs during breastfeeding
- The baby's vaccination plan belongs in the postpartum plan
- Caring for a newborn can affect the musculoskeletal system
- Sleep deprivation can complicate disease assessment
- What about pregnancy after spinal fusion or advanced ankylosis?
- What about osteoporosis?
- Pregnancy planning includes vaccines too
- An unexpected pregnancy: what should you do?
- Check your understanding 5
- Family planning is not only a women's-health issue
- Will my child inherit r-axSpA?
- Contraception belongs in the treatment discussion
- Assisted reproduction
- A practical preconception checklist
- The key message
- Where to go next
- Selected evidence sources
- contraception;
- pregnancy;
- fertility;
- breastfeeding;
- or becoming a parent.
This creates understandable questions:
- Can I get pregnant?
- Will pregnancy make my disease worse?
- Do I need to stop my biologic?
- Are NSAIDs safe?
- Can I have a vaginal delivery?
- Will an epidural be possible if my spine is fused?
- Can I breastfeed while taking treatment?
- Does my medication matter if my partner is the one becoming pregnant?
The most important principle is:
Pregnancy planning should protect both the pregnancy and control of the inflammatory disease.
Stopping effective treatment without a plan is not automatically safer.
In fact, poorly controlled inflammatory disease can create its own problems.
The best time to discuss pregnancy is therefore usually before conception, not after every medication has already been stopped.
Start before pregnancy when possible
A preconception visit does not need to be complicated.
The main questions are:
Is the disease reasonably well controlled?
Entering pregnancy with lower disease activity is generally preferable to entering pregnancy during a major flare.
Which medications am I taking?
Some can be continued.
Some may need modification.
Some should be stopped before conception.
Are there other important manifestations?
For example:
- inflammatory bowel disease;
- psoriasis;
- uveitis;
- significant hip disease;
- osteoporosis;
- or another medical condition.
Who needs to be involved?
Depending on the situation:
- rheumatology;
- obstetrics;
- maternal-fetal medicine;
- gastroenterology;
- ophthalmology;
- or anesthesiology.
The goal is to have a pregnancy-compatible disease-control plan before pregnancy begins whenever possible.
Check your understanding 1
A patient feels well on effective targeted therapy and wants to become pregnant.
Which plan makes more sense?
A
Stop everything immediately and contact the rheumatologist only if symptoms return.
B
Review each medication before conception and build a pregnancy-compatible treatment plan that keeps inflammatory disease controlled.
Answer: B.
Current EULAR recommendations specifically emphasize balancing medication risks against the risks of untreated maternal disease.
Can women with r-axSpA become pregnant?
Yes, many people with r-axSpA become pregnant and have successful pregnancies. The diagnosis alone does not establish infertility. Time to conception can be affected by age, disease activity, medicines, pain, sexual difficulties and unrelated reproductive conditions.
Research populations differ, and an observation about ovarian reserve or conception in one SpA group should not be treated as a personal prediction. If conception is delayed, review both partners’ health and medicines rather than assuming r-axSpA is the cause. [S06, S25]
When should difficulty conceiving be evaluated?
Do not assume that difficulty becoming pregnant must be caused by r-axSpA.
The usual causes of infertility still apply.
If conception is taking longer than expected, evaluation may involve both partners.
Depending on age and circumstances, clinicians may assess:
- ovulation;
- ovarian reserve;
- tubal factors;
- semen parameters;
- and other reproductive factors.
The rheumatology medication list should be part of that review.
NSAIDs can matter when trying to conceive
NSAIDs are commonly used for axial symptoms.
But prostaglandins are involved in ovulation.
Regular NSAID use around ovulation can reversibly interfere with follicle rupture in some women, potentially reducing fecundability.
This does not mean:
“Any ibuprofen prevents pregnancy.”
It means that if conception is delayed and NSAIDs are being used frequently, the medication strategy is worth discussing.
Do not stop necessary treatment without a replacement plan.
Fertility and men with r-axSpA
Most commonly used targeted therapies are not known to cause male infertility.
Current reproductive-rheumatology guidance considers paternal exposure to many antirheumatic treatments—including biologic therapies—compatible with conception.
One medication deserves special mention:
Sulfasalazine
Sulfasalazine is sometimes used when SpA includes substantial peripheral arthritis, although it is not an effective treatment for pure axial disease.
In men, it can temporarily reduce:
- sperm count;
- sperm motility;
- and fertility.
This effect is generally reversible after stopping the medication.
If conception is delayed and the male partner is taking sulfasalazine, this is worth discussing with the prescribing clinician.
Do not stop a biologic automatically when pregnancy begins
Plan treatment before conception when possible. The EULAR 2024 update, published in 2025, allows all TNF inhibitors throughout pregnancy after an individual risk–benefit assessment and permits non-TNF biologics when needed. It regards biologic DMARDs as compatible with breastfeeding. These recommendations do not make every medicine interchangeable, and the biologic recommendation does not apply to JAK inhibitors. [S06]
Discuss your exact medicine, disease control, the amount of evidence for that exposure and the current local product information. A society recommendation and a product label can differ; your team should explain how each informs the plan. The risk of stopping effective treatment belongs in the discussion alongside the risk of exposure.
TNF inhibitors: the largest pregnancy experience
TNF inhibitors include medications such as:
- adalimumab;
- infliximab;
- certolizumab;
- etanercept;
- golimumab.
Available data have not shown an increased overall rate of major congenital malformations attributable to TNF inhibitors.
Modern EULAR guidance allows TNF inhibitors throughout pregnancy when needed.
But the drugs are not identical.
Certolizumab is different in placental transfer
Certolizumab pegol has minimal to no active placental transfer because of its molecular structure.
This has made it a particularly useful treatment when continuous TNF inhibition is needed during pregnancy.
But an important modern point is:
A woman doing well on another TNF inhibitor does not automatically need to switch to certolizumab solely because she plans pregnancy.
Current guidance increasingly favors maintaining effective disease control rather than destabilizing a successful regimen simply to switch drugs.
The individual medication and pregnancy plan should still be reviewed.
Other TNF inhibitors cross the placenta more later in pregnancy
Several monoclonal TNF inhibitors cross the placenta increasingly during later pregnancy.
This does not mean they must always be stopped.
Current guidance allows continuation when maternal disease control requires it.
However, later fetal exposure can affect planning for certain live vaccines after birth.
That is why the baby’s pediatrician should know which biologic was used and when.
Infant vaccination needs a medication-specific plan
Give the pediatric team the names and timing of medicines used during pregnancy, including the last dose. Non-live vaccines can generally follow the usual local infant schedule after biologic exposure. [S06]
For live vaccines, the exact exposure and vaccine matter. The EULAR evidence review found reassuring observations for rotavirus vaccination after prenatal biologic exposure, whereas early BCG vaccination after TNF-inhibitor exposure raised a different concern. EULAR specifically permits usual-schedule rotavirus vaccination after prenatal TNF-inhibitor exposure; advice for other biologics can differ. [S06, S07]
Agree the schedule with the pediatric team using the specific drug, timing, local program and current product information. Reassuring observations are not a guarantee of zero risk, and a precaution for BCG should not become a blanket cancellation of the baby’s vaccines. Do not delay or omit infant vaccines on your own.
What about IL-17 inhibitors?
IL-17 inhibitors can be highly effective for r-axSpA.
Pregnancy experience is smaller than for TNF inhibitors.
Modern EULAR guidance is more permissive than older recommendations and allows non-TNF biologic therapy to be considered during pregnancy when clinically needed after individualized risk-benefit assessment.
That does not mean every IL-17 inhibitor has the same quantity of pregnancy data as TNF therapy.
If pregnancy is planned while using an IL-17 inhibitor, discuss:
- how well the disease is controlled;
- previous treatment failures;
- psoriasis;
- inflammatory bowel disease;
- alternative options;
- and the evidence available for the specific medication.
The decision should be drug-specific.
What about JAK inhibitors?
JAK inhibitors are different.
They are small-molecule targeted therapies, not biologics.
Human pregnancy safety data remain inadequate, and current product labeling generally recommends avoiding JAK inhibitors during pregnancy.
They usually require a planned interval between the final dose and conception.
The exact interval depends on the specific JAK inhibitor.
For example, U.S. upadacitinib labeling revised June 2026 advises effective contraception during treatment and for 4 weeks after the final dose. That interval belongs to this medicine; it is not a rule for every JAK inhibitor. [S22]
So if pregnancy is being considered:
do not simply stop a JAK inhibitor and start trying to conceive the next day.
Make a medication-specific transition plan with the treating clinician.
Check your understanding 2
Which statement is most accurate?
A
“All targeted therapies must be stopped once pregnancy begins.”
B
“TNF inhibitors have substantial reassuring pregnancy experience; other biologics may also be used when needed, while JAK inhibitors generally require discontinuation and pregnancy planning.”
Answer: B.
The correct plan depends on the exact medication.
What about NSAIDs during pregnancy?
NSAIDs require much more caution once pregnancy has begun.
In the United States, the FDA recommends avoiding NSAIDs at 20 weeks of pregnancy or later unless specifically advised by a clinician, because fetal kidney effects can reduce amniotic fluid.
If NSAID treatment is considered necessary between approximately 20 and 30 weeks, it should generally be used:
- at the lowest effective dose;
- for the shortest necessary duration;
- with additional monitoring when prolonged use is necessary.
At around 30 weeks and later, NSAIDs are generally avoided because of additional fetal cardiovascular risk.
Low-dose aspirin prescribed specifically for obstetric reasons is a separate situation and should not be confused with ordinary NSAID treatment.
“But NSAIDs are my main symptom treatment.”
That is exactly why pregnancy planning should happen before conception.
If a medication that normally controls symptoms becomes unsuitable later in pregnancy, the clinician may need another strategy.
The solution should not be:
“Just tolerate uncontrolled disease until delivery.”
Nor should it be:
“Continue over-the-counter NSAIDs because they are not prescription drugs.”
Over-the-counter ibuprofen and naproxen are still NSAIDs.
What about steroids?
Systemic glucocorticoids can sometimes be used during pregnancy when clinically necessary.
But current reproductive-rheumatology guidance recommends a more restrictive approach to:
- higher doses;
- prolonged exposure.
Long-term systemic steroids are not standard treatment for pure axial disease anyway.
When steroids are required for another inflammatory manifestation, clinicians balance:
- disease control;
- maternal risks;
- dose;
- and duration.
Local injections may present a different risk-benefit situation from chronic systemic therapy.
Pregnancy does not reliably switch axSpA “off”
Some inflammatory rheumatic diseases often become quieter during pregnancy.
Axial SpA is less predictable.
Studies show substantial variation.
Some women improve.
Some remain stable.
Others flare.
Studies report different flare rates in different SpA populations and use different definitions. Treatment interruption can contribute to loss of control, but no single percentage is a reliable forecast for an individual pregnancy. [S25]
So pregnancy should not be treated as a natural replacement for medication.
Check your understanding 3
A patient stops effective biologic therapy immediately after learning she is pregnant because she expects pregnancy itself to suppress the disease.
Is that expectation reliable in axSpA?
No.
AxSpA can remain active or flare during pregnancy.
Medication decisions should be planned rather than based on the assumption that pregnancy will control the disease.
Pregnancy can change how symptoms feel
Pregnancy itself can cause:
- low-back pain;
- pelvic discomfort;
- altered posture;
- ligamentous and mechanical changes;
- fatigue;
- sleep disturbance.
That can make disease assessment more difficult.
Not every increase in back or pelvic pain represents inflammatory axSpA activity.
The rheumatologist may need to distinguish:
pregnancy-related mechanical symptoms
from:
inflammatory disease activity.
That same inflammation-versus-mechanics distinction remains important throughout pregnancy.
What about MRI during pregnancy?
Sometimes imaging is needed.
MRI does not use ionizing radiation.
When clinically necessary, noncontrast MRI may be considered during pregnancy.
Gadolinium contrast requires a separate risk-benefit assessment and is generally avoided unless it is expected to provide important information that cannot reasonably be obtained otherwise.
The imaging question should still be:
What decision will this test help us make?
Does r-axSpA make pregnancy high risk?
The diagnosis does not predict a complication for an individual pregnancy. Studies have reported increased rates of some outcomes, including preterm birth, smaller infants and cesarean delivery, but populations, disease activity and results vary. These findings should support coordinated obstetric and rheumatology care rather than a prediction that a particular pregnancy will go badly. Discuss the monitoring appropriate to your disease, medicines and other health conditions. [S25]
Does r-axSpA mean I need a cesarean section?
No.
r-axSpA by itself does not automatically require cesarean delivery.
Many women with ankylosing spondylitis/r-axSpA deliver vaginally.
Population studies do show a higher rate of cesarean delivery, particularly elective cesarean delivery, but this does not prove that cesarean delivery is medically necessary for everyone with the disease.
The delivery plan depends on:
- ordinary obstetric indications;
- hip mobility;
- spinal structure;
- ability to position for labor;
- and other individual factors.
Hip disease can matter for delivery
Severe hip disease can limit the positions available during labor.
If hip motion is substantially restricted, tell the obstetric team before labor.
This allows time to discuss:
- positioning;
- labor management;
- and whether structural limitations create any special considerations.
Most patients with r-axSpA do not have hip limitation severe enough to dictate the method of delivery.
The spine matters for anesthesia planning
Many patients with r-axSpA can receive ordinary obstetric anesthesia.
But substantial spinal disease can make procedures technically more difficult.
Possible challenges include:
- reduced lumbar flexibility;
- fused spinal segments;
- difficult landmarks for epidural or spinal placement;
- limited neck mobility;
- and, in severe disease, potential difficulty with airway management if general anesthesia becomes necessary.
This does not mean:
“You cannot have an epidural.”
It means severe structural disease deserves planning.
When should anesthesiology be involved early?
Consider discussing an antenatal anesthesia consultation when there is:
- substantial spinal ankylosis;
- severe kyphosis;
- markedly limited lumbar movement;
- major cervical limitation;
- previous difficult epidural or spinal procedure;
- previous spinal surgery;
- or another significant airway/spinal issue.
Early planning is much easier than solving an unexpected technical problem during urgent labor or cesarean delivery.
Check your understanding 4
A pregnant patient has advanced spinal ankylosis and severe cervical restriction.
Best plan?
A
Wait until active labor to mention it.
B
Let the obstetric team know in advance and consider antenatal anesthesiology assessment.
Answer: B.
Planning does not mean cesarean delivery is inevitable.
It means the team understands the anatomy before anesthesia is urgently needed.
What happens after delivery?
The postpartum period deserves its own treatment plan.
AxSpA may flare after pregnancy.
Recent systematic evidence suggests postpartum flares are common, particularly in axial SpA.
Several factors may contribute:
- medication interruption;
- hormonal and immune changes;
- sleep deprivation;
- physical demands of caring for a newborn;
- and restarting treatment too slowly.
Do not assume:
“Once the baby is born, I can wait several months before thinking about rheumatology.”
Postpartum follow-up should be planned before delivery.
If a biologic was stopped during pregnancy, when can it be restarted?
Often quite soon postpartum when it is medically appropriate.
The exact timing depends on:
- infection;
- cesarean or other surgical healing;
- obstetric complications;
- the medication;
- and the treatment plan.
Current guidance supports restarting needed TNF therapy postpartum rather than allowing preventable maternal disease activity to return.
Breastfeeding and biologics
This is another area where guidance has become more reassuring.
Current EULAR recommendations consider biologic DMARDs compatible with breastfeeding.
Large protein biologics enter breast milk in very small amounts, and the infant’s gastrointestinal system is expected to absorb little intact drug.
TNF inhibitors have particularly extensive reassuring breastfeeding experience.
For newer biologics, the evidence base may be smaller, but modern guidance has moved away from automatically advising patients to choose between:
breastfeeding
and:
effective biologic disease control.
Often both are possible.
JAK inhibitors are different during breastfeeding
JAK inhibitors are small molecules and are more likely than biologics to enter breast milk.
They are generally not recommended during breastfeeding.
Again, the exact product matters.
U.S. upadacitinib labeling revised June 2026 advises against breastfeeding during treatment and for 6 days after the last dose. Other drugs need their own instructions. [S22]
If breastfeeding is important, this should be discussed before delivery, so postpartum inflammatory control has a compatible plan.
NSAIDs during breastfeeding
Several NSAIDs can be compatible with breastfeeding, depending on the specific drug and maternal circumstances.
But medication choice should still be reviewed because NSAIDs differ in:
- half-life;
- maternal risks;
- and infant exposure.
Do not assume all over-the-counter medications are automatically appropriate.
The baby’s vaccination plan belongs in the postpartum plan
Before delivery, arrange for the pediatric team to receive the prenatal medication record. The infant-vaccination section above explains why the exact drug, timing and vaccine matter.
Caring for a newborn can affect the musculoskeletal system
The postpartum period adds repetitive physical tasks:
- lifting;
- carrying;
- feeding;
- bending over a crib;
- sitting for long periods;
- interrupted sleep.
These can produce mechanical pain even when inflammatory disease is controlled.
Useful adaptations may include:
- feeding positions that support the back and arms;
- bringing the baby toward you rather than repeatedly bending forward;
- changing-surface height;
- alternating carrying positions;
- asking for help with prolonged lifting;
- and resuming conditioning gradually.
Postpartum back pain is not automatically an axSpA flare.
Sleep deprivation can complicate disease assessment
A newborn can dramatically alter:
- sleep;
- fatigue;
- pain sensitivity;
- mood;
- concentration.
Those changes can raise symptom scores.
The rheumatologist should still look for inflammation—but should also recognize the postpartum context.
A high pain or fatigue score is not automatically proof that the biologic has failed.
What about pregnancy after spinal fusion or advanced ankylosis?
Pregnancy can still be possible.
The main considerations may become more practical:
- baseline mobility;
- balance;
- hip range;
- pulmonary/chest-wall limitation if severe;
- delivery positioning;
- anesthesia access;
- and fracture risk.
This is a situation where multidisciplinary planning can be especially valuable.
The presence of ankylosis does not itself mean pregnancy is contraindicated.
What about osteoporosis?
If significant osteoporosis or previous spinal fracture is present, pregnancy and postpartum physical demands should be discussed in advance.
Questions may include:
- fracture risk;
- exercise;
- lifting;
- calcium/vitamin D adequacy;
- and timing of osteoporosis medications.
Some osteoporosis treatments are not appropriate around pregnancy and have long skeletal retention.
That topic requires a medication-specific preconception plan.
Pregnancy planning includes vaccines too
Before pregnancy, it is useful to review whether routine vaccinations are current.
This becomes especially important for patients receiving immunomodulatory treatment.
Some live vaccines may need to be given before pregnancy or before immunosuppression.
Non-live vaccines can often be administered during pregnancy when otherwise indicated.
The obstetric, primary-care and rheumatology teams can coordinate this.
An unexpected pregnancy: what should you do?
Do not panic.
And do not assume that every medication exposure has harmed the pregnancy.
Contact the prescribing clinician promptly and provide:
- medication name;
- dose;
- last dose;
- estimated gestational age.
Some medications can simply be continued.
Some should be stopped or changed.
Some exposures that are not recommended for planned pregnancy may still have reassuring data after accidental early exposure.
The appropriate response is:
medication-specific assessment
not:
automatic treatment withdrawal or assumption of fetal harm.
Check your understanding 5
A patient discovers she is pregnant while taking a targeted medication.
What is the safest general next step?
A
Stop every prescription immediately.
B
Take an extra dose before anyone changes the plan.
C
Contact the prescribing clinician promptly for medication-specific guidance.
Answer: C.
The safety profile differs substantially among treatments.
Family planning is not only a women’s-health issue
Review the non-pregnant partner’s medicines too. Paternal exposure is a different question from maternal exposure during pregnancy or breastfeeding; instructions for one should not automatically be applied to the other. EULAR considers paternal exposure to many antirheumatic medicines, including biologics, compatible with conception. [S06]
Sulfasalazine can reversibly reduce sperm quality, so delayed conception warrants a medication review together with investigation of other causes. This does not mean every man needs to stop sulfasalazine or an effective biologic before trying to father a child.
Will my child inherit r-axSpA?
Family history can increase susceptibility, but r-axSpA is not inherited as a certainty and HLA-B27 is not a yes-or-no prediction of future disease. Discuss your family history with the treating team rather than applying one inheritance percentage to every family.
ACR’s 2026 summary supports counselling about risk in first-degree relatives and conditionally recommends against routine genetic testing of those relatives. A relative with concerning symptoms needs clinical assessment; an otherwise well child should not be treated as having axSpA because a parent has it. [S01]
Contraception belongs in the treatment discussion
If a medication should not be used during pregnancy—such as a JAK inhibitor—the patient should know:
- what contraception is recommended;
- for how long;
- and how long to wait after stopping treatment before trying to conceive.
This should ideally be discussed when the medication is prescribed, not years later.
The same applies when pregnancy is definitely not desired.
Reproductive planning is part of medication safety.
Assisted reproduction
Patients with r-axSpA may use:
- ovulation induction;
- intrauterine insemination;
- IVF;
- or fertility preservation
for the same reasons as anyone else.
The rheumatologist should know when assisted reproduction is planned because:
- medication may need coordination;
- disease activity should ideally be controlled;
- NSAID use may need review;
- and physical symptoms can affect procedures or positioning.
There is no general rule that axSpA prevents assisted reproduction.
A practical preconception checklist
Before trying to conceive, ask:
DISEASE
☐ Is my axSpA reasonably controlled?
☐ Any active uveitis?
☐ Active psoriasis?
☐ Active IBD?
☐ Major hip or structural problem?
MEDICATION
☐ Which medications can continue?
☐ Which need to stop or change?
☐ Is there a medication-specific washout period?
☐ Am I relying heavily on NSAIDs?
☐ What will control disease if something is stopped?
GENERAL HEALTH
☐ Vaccines reviewed?
☐ Smoking?
☐ Bone health concerns?
☐ Other medical conditions?
☐ Prenatal vitamin/folic acid discussed with obstetrics?
DELIVERY PLANNING
If substantial structural disease:
☐ Does obstetrics know?
☐ Is hip mobility significantly limited?
☐ Would antenatal anesthesiology review be helpful?
POSTPARTUM
☐ What medication will I use after delivery?
☐ Is it compatible with breastfeeding?
☐ When will rheumatology follow-up occur?
☐ Does the pediatrician need information about late-pregnancy biologic exposure?
The key message
Pregnancy planning in r-axSpA should not begin with:
“Which medications must I stop?”
It should begin with:
“How do we keep the disease safely controlled before conception, during pregnancy and after delivery?”
For many patients:
- pregnancy is achievable;
- pregnancy outcomes are favorable;
- vaginal delivery remains possible;
- effective biologic treatment can often continue;
- and breastfeeding can often coexist with appropriate rheumatologic therapy.
The important exceptions—particularly JAK inhibitors, later-pregnancy NSAID use, and some medication-specific situations—should be addressed before they create a problem.
And the postpartum period should not be forgotten.
A healthy pregnancy plan includes a healthy mother whose inflammatory disease remains appropriately treated.
Where to go next
- Vaccines and infection safety
- Choosing targeted therapy
- Eye, skin and bowel disease
- Bone health
- Everyday life
- Prepare for a visit
- Back to the patient guide
Selected evidence sources
S01. American College of Rheumatology / Spondylitis Association of America / SPARTAN. 2026 axial spondyloarthritis guideline summary. Posted June 24, 2026. Source.
S06. Rüegg L, et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann Rheum Dis. 2025;84:910–926. doi:10.1016/j.ard.2025.02.023. Source.
S07. Pluma A, et al. Antirheumatic drugs in reproduction, pregnancy, and lactation: a systematic literature review informing the 2024 update of the EULAR recommendations. Ann Rheum Dis. 2025;84:1561–1590. doi:10.1016/j.ard.2025.02.021. Source.
S22. AbbVie. RINVOQ (upadacitinib), US prescribing information. Revised June 2026; reproductive precautions and medication safety. Source.
S23. US Food and Drug Administration. NSAIDs at 20 weeks of pregnancy or later: fetal kidney effects and low amniotic fluid. Drug safety communication. Source.
S24. American College of Obstetricians and Gynecologists. Committee Opinion 723: Guidelines for Diagnostic Imaging During Pregnancy and Lactation. 2017, with subsequent correction. Source.
S25. Gross N, Molto A, Felten R. Spondyloarthritis in the peripartum period: a systematic review of current knowledge and clinical implications. 2026. doi:10.1177/1759720X261444224. Source.
Sources checked: October 1, 2026. Examples and checkpoints are fictional educational scenarios.
Educational information only. This article supports discussion with your clinicians and does not give an individual diagnosis or medication prescription.